DocGo SPAC Presentation Deck

Made public by

sourced by PitchSend

2 of 30

Creator

Doc Gosh logo
Doc Gosh

Category

Healthcare

Published

May 2021

Slides

Transcriptions

#1© 2021 All Rights Reserved DocGo DOCGO WHERE TELEHEALTH STOPS, WE GO INVESTOR PRESENTATION MAY 2021#2Disclaimer DOCGO This presentation contemplates a business combination pursuant to a merger agreement, by and among Ambulnz Inc. (dba "DocGo"), Motion Acquisition Corp. ("Motion"), and a wholly owned subsidiary of Motion, dated as of March 9, 2021. This presentation discusses the proposed transaction and does not purport to be all-inclusive or to give you any legal, tax or financial advice. This presentation does not constitute or involve, and should not be taken as constituting or involving, the giving of any investment advice, the making of any representation, warranty or covenant whatsoever, or as a recommendation with respect to the voting, purchase or sale of any security or as to any other matter by DocGo, Motion or any other person. Although the information contained herein is believed to be accurate, DocGo and Motion, as well as each of their respective directors, officers, shareholders, members, partners and representatives, expressly disclaim liability for, and makes no expressed or implied representation or warranty with respect to, any information contained in or omitted from this presentation, or any other information or communication (whether written or oral) transmitted to any prospective investor. Only those representations and warranties made in a definitive agreement with any person shall have any legal effect. This presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination between DocGo and Motion or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to buy any security of Motion, any company forming a part of DocGo or any of their respective affiliates. There shall not be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Investors should make their own independent investigation of DocGo and Motion before investing in any securities. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE PERFORMANCE. Use of Projections and Financial Information This presentation contains financial forecasts relating to the anticipated future financial performance of the proposed combination of DocGo and Motion and are subject to risks and uncertainties that could cause actual results to differ materially from those statements and should be read with caution. They are subjective in many respects and thus susceptible to interpretations and periodic revisions based on actual experience and recent developments. While presented with numerical specificity, the projections were not prepared in the ordinary course and are based upon a variety of estimates and hypothetical assumptions made by management of DocGo and Motion with respect to, among other things, general economic, market, interest rate and financial conditions, the availability and cost of capital for future investment, and competition within DocGo's markets. The projections were not prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for prospective financial information or generally accepted accounting principles in the United States of America ("GAAP"). None of the assumptions underlying the projections may be realized, and they are inherently subject to significant business, economic and competitive uncertainties and risks, all of which are difficult to predict and many of which are beyond the control of DocGo and Motion. Accordingly, there can be no assurance that the assumptions made in preparing the projections will prove accurate, and actual results may materially differ. Furthermore, while all projections are necessarily speculative, DocGo and Motion believe that prospective financial information covering periods beyond 12 months from its date of preparation carries increasingly higher levels of uncertainty and should be read in that context. For these reasons, as well as the bases and assumptions on which the projections were compiled, the inclusion of the information set forth below should not be regarded as an indication that the projections will be an accurate prediction of future events, and they should not be relied on as such. Neither DocGo nor Motion or any of their respective affiliates, advisors or other representatives has made, or makes, any representation to any stockholder or prospective investor regarding the information contained in the projections and, except as required by applicable securities laws, neither DocGo nor Motion intends to update or otherwise revise the projections to reflect circumstances existing after the date when made or to reflect the occurrences of future events even in the event that any or all of the assumptions are shown to be in error. Non-GAAP Financial Information This presentation also includes references to financial measures that are calculated and presented on the basis of methodologies other than in accordance with GAAP, such as Earnings Before Interest, Tax, Depreciation and Amortization ("EBITDA") and Adjusted EBITDA. As a result, such information may not conform to SEC Regulation S-X and may be adjusted and presented differently in Motion's filing with the SEC. Any non-GAAP financial measures used in this presentation are in addition to, and should not be considered superior to, or a substitute for, financial statements prepared in accordance with GAAP. Non-GAAP financial measures are subject to significant inherent limitations. The non-GAAP measures presented herein may not be comparable to similar non-GAAP measures presented by other companies. This information may be presented differently in future filings by the company with the SEC. © 2021 All Rights Reserved - DocGo 1#3Disclaimer (cont'd) DOCGO Market and Industry Data Market data and industry data used throughout this presentation is based on information derived from third party sources, the knowledge of the management teams of DocGo and Motion regarding their respective industries and businesses and respective management teams' good faith estimates. While management of DocGo and Motion believe that the third party sources from which market and industry data has been derived are reputable, DocGo and Motion have not independently verified such market and industry data, and you are cautioned not to give undue weight to such market and industry data. Additional Information and Where to Find It This presentation relates to a proposed transaction between DocGo and Motion. Motion intends to file a registration statement on Form S-4 with the SEC, which will include a document that serves as a prospectus and proxy statement of Motion, referred to as a proxy statement/prospectus, and certain related documents, to be used at the meeting of Motion stockholders to approve the proposed business combination and related matters. Investors and security holders of Motion are urged to read the registration statement, the proxy statement/prospectus, and any amendments thereto, and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about DocGo, Motion, and the proposed transaction. The definitive proxy statement will be mailed to Motion stockholders as of a record date to be established for voting on the proposed business combination. Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Motion, once such documents are filed, through the website maintained by the SEC at www.sec.gov. The documents filed by Motion with the SEC also may be obtained free of charge at Motion's website at https://motionacquisition.com or upon written request to Motion's counsel, Graubard Miller, 405 Lexington Avenue, New York, NY 10174. Solicitation Participants DocGo and Motion and their respective officers and directors, under SEC rules, may be deemed to be participants in the eventual solicitation of proxies of Motion's stockholders in connection with the proposed transaction. Prospective investors may obtain more detailed information regarding the names and interests in the proposed transaction of such individuals in Motion's filings with the SEC. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be contained in the proxy statement/prospectus when available. You may obtain free copies of these documents as described in the preceding paragraph. Forward Looking Statements Certain statements included in this presentation are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of DocGo's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of DocGo and Motion. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions. Further, these forward-looking statements are subject to a number of risks and uncertainties, including: the conditions to the completion of the merger, including the required approval by DocGo's and Motion's stockholders, may not be satisfied on the terms expected or on the anticipated schedule; the parties' ability to meet expectations regarding the timing and completion of the merger; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the approval by Motion's stockholders of an amendment to Motion's organizational documents to extend the date by which Motion must complete its initial business combination in order to have adequate time to close the proposed transaction; the outcome of any legal proceedings that may be instituted against Motion related to the merger or the merger agreement; and the amount of the costs, fees, expenses and other charges related to the merger; the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination; failure to realize the anticipated benefits of the proposed business combination; risks relating to the uncertainty of the projected financial information with respect to DocGo; DocGo's ability to successfully expand its service offerings; competition; the uncertain effects of the COVID-19 pandemic; and those factors discussed in the registration statement, proxy statement/prospectus, and other documents filed, or to be filed, by Motion with SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither DocGo nor Motion presently know or that DocGo and Motion currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect DocGo's and Motion's expectations, plans or forecasts of future events and views as of the date of this presentation. DocGo and Motion anticipate that subsequent events and developments will cause DocGo's and Motion's assessments to change. However, while DocGo and Motion may elect to update these forward-looking statements at some point in the future, DocGo and Motion specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing DocGo's and Motion's assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. © 2021 All Rights Reserved DocGo - 2#4Disclaimer (cont'd) DOCGO Forward Looking Statements (cont'd) Any financial projections in this presentation are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond DocGo's and Motion's control. While all projections are necessarily speculative, DocGo and Motion believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. The assumptions and estimates underlying the projected results are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the projections. The inclusion of projections in this presenttion should not be regarded as an indication that DocGo and Motion, or their respective representatives and advisors, considered or consider the projections to be a reliable prediction of future events. This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in Motion and is not intended to form the basis of an investment decision in Motion. All subsequent written and oral forward-looking statements concerning DocGo and Motion, the proposed business combination or other matters and attributable to Motion, DocGo, or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Other Disclaimers No representation or warranty, express or implied, can be made or is made by DocGo or Motion as to the accuracy or completeness of any such information. Except where otherwise indicated, this presentation speaks as of the date hereof and is necessarily based upon the information as of the date hereof, all of which are subject to change. DocGo and Motion have no obligation to update, bring-down, review or reaffirm this presentation. Under no circumstances should the delivery of this presentation imply that any information or analyses included in this presentation would be the same if made as of any other date. Nothing contained in this presentation is, or shall be relied upon as, a promise or representation as to the past, present or future. This presentation provides summary information only and is being delivered solely for informational purposes. The recipient of this presentation acknowledges that: DocGo and Motion do not provide legal, tax or accounting advice of any kind. It is not relying on DocGo or Motion for legal, tax or accounting advice, and that the recipient should receive separate and qualified legal, tax and accounting advice in connection with any transaction or course of conduct. Nothing contained herein shall be deemed to be a recommendation from DocGo or Motion to any party to enter into any transaction or to take any course of action. This presentation is not intended to provide a basis for evaluating any transaction or other matter. Neither DocGo nor Motion shall have any liability, whether direct or indirect, in contract or tort or otherwise, to any person in connection with this presentation. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAS ANY REGULATORY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER OR SOLICITATION OF ANY SECURITIES. ● ● . © 2021 All Rights Reserved - DocGo 3#5Our Brand and Company Culture Where basic telehealth providers stop, we go. Where public health emergencies need a response, we go. Where homebound populations benefit from onsite treatment, we go. Where long waits in busy emergency rooms do more harm than good, we go. And when all reason says it can't be done, leave well enough alone and quit while you're ahead, we do what our Company has always done. DocGo. We go. © 2021 All Rights Reserved - DocGo Our Model DOCGO TeleHealth Plus ambulnz Mobility Solutions Proprietary Technology Platform Care Logistics Platform Fulfilling the Promise of Telehealth by Enabling the "Last-Mile" Delivery of Healthcare 4#6DocGo at a Glance Key Highlights 82%+ 2019-2021E Revenue CAGR Positive and Increasing EBITDA FY 2021 Revenue Guidance Prior $155mm (a) As of May 15, 2021. © 2021 All Rights Reserved - DocGo Updated $160mm+ DOCGO 2,000+ Employed Providers (a) 492%+ TeleHealth Plus 2019-2021E Growth M Leveraging a proprietary technology platform and care logistics expertise to provide high quality, efficient "last-mile" healthcare delivery services 2,200,000+ Cumulative Patient Interactions(a) 01 5#7Where Traditional Care Stops, DocGo Keeps Going TeleHealth Plus DOCGO © 2021 All Rights Reserved - DocGo Mobility X DOCGO Traditional Care Patients are restricted by outdated logistics and expensive transportation solutions Limited options to get treated at home or on-site X Current telehealth offerings do not provide immediate in-person care or follow-up as needed X Traditional Care vs. TeleHealth Plus DocGo TeleHealth Plus Solution Mobility solutions that are enabled by highly coordinated and efficient logistics capabilities TeleHealth Plus offering goes far beyond traditional telehealth capabilities, delivering true "last-mile" services Unique solution set plugs seamlessly into existing care ecosystem 6#8Telemedicine is Just Talk - TeleHealth Plus is DOCGO Hands On DocGo. We're There. Vaccinations Bloodwork © 2021 All Rights Reserved - DocGo blood Leveraging Advanced, Mobile Technologies to Deliver Robust Services Oral Medicine Administration IV Hydration $15 ✓ Wound Care ✓ Note: EMT = Emergency Medical Technician, LPN = Licensed Practical Nurse, LVN = Licensed Vocational Nurse. Mobile Imaging For Patients... At home treatment is convenient, comfortable and results in an improved patient experience EKG Accessibility to health professionals promotes better patient compliance with discharge treatment plans More focused care reduces unnecessary hospital readmissions For Providers... M DocGo employed providers, consisting of paramedics and EMTS, provide care at a lower cost than LPNs/LVNs or physicians can Reduces overall healthcare costs by preventing unnecessary flow of patients into healthcare facilities 7#9Differentiated Approach Creates Efficiency and Cost Savings I I I 69 Leverages paramedics, EMTS, CNAs and LPNs to provide care, lowering employment costs for hospitals and patients vs. traditional methods EMT EMTS, Paramedics, CNAS and LPNs have significantly lower hourly costs Enabling Dramatic TeleHealth Plus Cost Advantage Vaccination Paramedic © 2021 All Rights Reserved - DocGo CNA Can scale rapidly in new markets by utilizing temporary CNAs and LPNs through local agency hiring Bloodwork IV Hydration ■ Doc Go 8 Source: Management estimates. Note: Figures above are presented for illustrative purposes only. CNA Certified Nursing Assistant. LPN Able to train up LPNs and CNAs in -1.5 weeks 1 I 1 Cost of common procedures, such as vaccination and bloodwork, are executed at a fraction of the industry average Cost per patient Vs Wound Care Industry Average ၃ Physician DOCGO Currently facing a national shortage and significantly more expensive per hour Oral Medicine Administration Nurse Practitioner EKG 8#10Transportation Serves as Foundation for Operational Leverage Drives margin improvement and competitive advantage Transportation Model Advantages Competitive Differentiators ON ambulnz Innovative JV model Highly predictable transport volume Integrated platform changes the way facilities manage patient transports, improves operational efficiencies and aligns incentives ● Employed providers and not contractors Lays profitable foundation to upsell idle time © 2021 All Rights Reserved - DocGo ● ● ● ● ● Provides opportunity to build highly defensible model by selecting mix of transportation / TeleHealth Plus per geography to optimize gross margin Differentiates against pure plays by offering two different products to build in geography credibility and cross sell with major providers Superior employee attraction and retention model to source the best talent Logical framework to execute M&A strategy combined with the ability to grow margins and cash flow ratios Pediatrics / Neonatal Intensive Care Unit Critical Care Transport ambulnz ambulnz AMBULETTE HE AT&T uez SHARED REQUEST#105 DOCGO Promised Pickup california.ambuinz-dev.net C 00:32 Pred rep A 00:40 shtet Picki A 00:32 Curre Grap Off A 00:40 Lynwood KA m MT Basic Life Support Advanced Life Support Wheelchair Accessible Vehicle Ambulette Fully integrated solution provider facilitating high-quality, efficient patient transportation across all sites of care Parame 21:31 Pip HTT Se 21:31 22:27 22:27 Mke The M 1LL MY Mo May New York Eendrary of M for The MENT www. dimbuln l Car ANTE Ele 0 6 9 MORE HAVE#11Purpose-Built Technology Platform Core Functionality and Benefits Streamlined ordering process to reduce burden on staff Integration of electronic health records to enhance functionality & billing/collections Epic Allscripts Easy ordering with no manual information transfer Real-time visibility into transport status and ordering ✓ Fully integrated with bed management systems Predictive resource allocation to estimate patient discharge For Patients and Families © 2021 All Rights Reserved - DocGo For Care Providers For Facilities For Peace of Mind Two apps. One location-based dispatch system. Connected. ACCEPT REQUESTED PICKUP ☐ SERVICE TYPE O 12:33 PM UNIT 900 ETA 13:10 St. Francis Medical Center 3630 E Imperial Hwy, Lynwood, CA 90262 DOCGO SERVICE LEVEL REJECT ETA 11/19 13:10 UNIT 900 CALL WILL Santa Anita Convalescent Hospital 5522 Gracewood Ave, Arcadia, CA 11/19 12:36 Torrance Long Beach One Way Discharge, BLS PICKUP Discharge, BLS One Way 11/19 12:36 Stefan Req Berger DESTINATION Anahei aheim 3 SERVICE LEVEL 38 REQUESTED PICKUP TRIP TYPE O sadena O FACESHEET PATIENT DEMOGRAPHICS & USER IW 10 DOB 112 t Name R-10 X#12Our Footprint and Reach Our Footprint Currently operating in 23 US states and the UK Licensed to operate in 29 states; licenses pending in 14 additional states <1% market penetration today © 2021 All Rights Reserved - DocGo DOCGO Mobility Only TeleHealth Plus Only Mobility and TeleHealth Plus 11#13● ● JV Partners Help Drive Predictable Growth F FRESENIUS Premier global dialysis provider with 2,600+ dialysis centers and 205k+ patients Transportation JV partner uchealth #1 health care system in Colorado, also serving Southern Wyoming and Western Nebraskaa) Transportation JV partner $500M+ per year combined revenue opportunity (b) ● (a) According to U.S. News and World Report. (b) Based on management estimates. © 2021 All Rights Reserved - Doc Go ● Jefferson. Largest Philadelphia region hospital system with 14 hospitals, 5 urgent care, 22 rehab and 19 outpatient centers Transportation and TeleHealth Plus JV partner RXR Leading real estate owner and operator in New York City TeleHealth Plus JV partner, providing on-site testing, monitoring, reporting and verification $ Highly recurring and predictable revenue DOCGO 224 FFRES GOK ambulnz Evergreen contract structure with multi-year cancellation notice periods DocGo is in advanced talks with several large hospital systems and national healthcare companies to expand its JV partnerships National footprint across JVs TM 12#14Illustrative Customers & Partners Tailored Go-to-Market for each Customer Segment STATE OF CORRECTIONS AND RE OF CALIFORNIA MIAMI DADE COUNTY Government City of Philadelphia PHILADELPHIA PHL INTERNATIONAL AIRPORT NEW YORK Department STATE of Health © 2021 All Rights Reserved - DocGo BARCLAYS CENTER BROOKLYN CITY HBO Enterprise / Corporates Borgata CASINO & SPA EQUINOX GoodP JAVITS CENTERⓇ NFL Carnival Uber BLADE MD1 RXR W HOTELS DOCGO Health Systems FRESENIUS MEDICAL CARE Jefferson Mount Sinai HCA Healthcare™ O uchealth Long Island Select Healthcare, Inc. Northwell Health SM 13#15Significant Market Opportunity $95 billion market opportunity leaving long runway for rapid growth U.S. Total Addressable Market Medical Transportation $13 B Last-Mile Home Medication Administration $12 B © 2021 All Rights Reserved - Doc Go $95 Billion Last-Mile Home Health Services $35 B Last-Mile Urgent Care $35 B Source: McKinsey "Telehealth: A quarter-trillion-dollar-post-COVID-19 reality" report published 5/1/20 and management estimates. ● ● DOCGO Payers, providers and patients are motivated to push services to the home Approx. $250B or 20% of all Medicare, Medicaid & Commercial outpatient, office and home health spend could be virtual However, approx. $80B of this spend requires some form of physical follow up that lacks a solution today The medical transportation industry remains very fragmented and is expected to continue to grow steadily, driven by an increasingly aging population and rising prevalence of chronic diseases 14#16Experienced Management Team Presenting Today Stan Vashovsky Co-Founder, Chief Executive Officer Founded DocGo in 2015 with the vision to revolutionize medical transportation and healthcare delivery Previously an executive for services innovations at Philips Healthcare 25+ years of healthcare experience including in the field as a paramedic Anthony Capone President © 2021 All Rights Reserved - DocGo DOCGO Vrenely Munoz Chief Revenue Officer ● ● Ari Moradmand Chief Technology Officer DOCGO Andre Oberholzer Chief Financial Officer Joined in 2015 with experience developing companies throughout their business lifecycle including M&A / integration Previously in financial roles at Philips and Altegrity and CFO of WageWorks 20+ years of finance and operations experience Norm Rosenberg CFO of Ambulnz Holdings, LLC Rosemarie Milano VP, Human Resources 15#17Key Takeaways Significant market and growth opportunity with limited current market penetration Early stages of accelerating recurring revenue growth Unique value proposition to healthcare systems and patients Defensible competitive advantages in technology / network Highly attractive financial profile with significant operating leverage Mission-driven company with experienced founder-led management DOCGO © 2021 All Rights Reserved - DocGo 16#18→ Financial Overview#19Highly Attractive Financial Characteristics Significant revenue growth opportunity with limited existing penetration Visibility to recurring revenue growth with existing JV partners Scalable business model with robust operating leverage DOCGO Capital efficient approach enables rapid expansion in existing and into new markets © 2021 All Rights Reserved - DocGo 18#20Recurring, Predictable Revenue Model Description Revenue Model ● Mobility Solutions Data-driven market-by-market approach to identify highly visible, recurring transportation needs by provider Base rate and average transport distance largely dependent upon geography Base rate typically references a Medicare fee schedule and has historically grown annually [$) Fee per Trip x Trips per Shift Base Rate + (Loaded Miles x Per Mile Rate) © 2021 All Rights Reserved - DocGo DOCGO TeleHealth Plus Solutions Contractual established relationships with healthcare providers leads to a consistent demand for services Fees for solutions delivered to healthcare providers; requiring onsite access to patients and supported by recurring needs for tests and services Predominantly state and municipality pay today; exploring roadmap to expand to commercial and healthcare provider payers & Healthcare Utilization X Fee for Service Contractual arrangements delivering significant recurring revenue and a high degree of visibility into long-term revenue growth 19#21Strong Growth Trajectory and Margin Profile ($ in millions) $40 2018A % growth 28.5% $8 2018A % margin 20.8% $48 2019A 21.4% $13 2019A 27.3% Revenue $94 2020A © 2021 All Rights Reserved - DocGo 95.3% Gross Profit $32 2020A 33.9% $160 2021E 70.2% $64 2021E 40.0% Note: PCAOB audits for 2019 and 2020 are in process. (a) Free Cash Flow is defined as Adjusted EBITDA less Capital Expenditures. $267 2022E 71.7% $117 2022E 44.0% ($31) 2018A % margin NM ($17) 2019A NM ($18) ($34) 2018A 2019A % of Adjusted EBITDA NM NM Adjusted EBITDA ($7) 2020A NM Free Cash Flow(a) ($9) 2020A NM $6 2021E 3.9% $4 2021E 66.6% $43 2022E 16.1% $38 2022E 88.4% DOCGO ● ● ● Substantial growth through the expansion of existing contracts and markets New market expansion within existing joint venture relationships contributes to revenue acceleration TeleHealth Plus acceleration drives operating leverage and margin expansion Capital efficient model to support continued growth Strong platform for acquisitions 20#22Q1 2021 Financial Update ($ in millions) $13.4 Q1 2020 ($4.5) Q1 2020 © 2021 All Rights Reserved - DocGo Revenue 270% YoY Adjusted EBITDA $49.6 Q1 2021 $0.7 Q1 2021 DOCGO Preliminary First Quarter 2021 Financial Highlights and Full-Year Outlook • Excluding Covid-related testing, Q1 revenue more than doubled ● ● TeleHealth Plus revenue increased to nearly $30 million, compared to $0.5 million in Q1 2020 First Quarter 2021 Business Highlights Expanded TeleHealth Plus offerings, with home visit programs for Long Island Select Healthcare in New York and Martin Luther King Hospital in Los Angeles ● DocGo is raising its outlook for full-year 2021 revenue guidance from $155 million to +$160 million Completed rollout of 40 mobile testing units for NYC Health + Hospitals and NYC Test & Trace Corps, and became a leading facilitator of COVID vaccinations in NY State 21#232 Transaction Overview#24Pro Forma Capitalization & Ownership Estimated Transaction Sources & Uses ($ in millions) SPAC Cash in Trust PIPE Investor Cash Total Sources Sources Cash to Balance Sheet Transaction Expenses Total Uses © 2021 All Rights Reserved - DocGo Uses $115 $125 $240 $205 $35 $240 (a) Assumes no redemptions of public shares and excluding warrants. (b) Does not include an aggregate 5.0M seller earnout shares subject to vesting upon attainment of stock price targets ranging from $12.50 to $21.00 over periods ranging from one to five years. Excludes Motion warrants. Post-Money Valuation at Close ($ in millions) DocGo Illustrative Share Price Pro forma Shares Outstanding Total Equity Value (+) Proforma Net Debt at Close Pro forma Enterprise Value 10% 3% Pro forma Transaction 11% DOCGO (a)(b) Illustrative Post-Transaction Ownership 76% $10.00 110.5 $1,105 (205) $900 (b) ■ SPAC shareholders ■ Seller rollover ■ PIPE shareholders ■ SPAC sponsor 23#25Comparable Company Benchmarking 2019A-2022E Revenue CAGR 2021E Gross Profit Margin 2019A-2022E Gross Profit CAGR + DocGo 77% © 2021 All Rights Reserved - DocGo DocGo 40% DocGo 107% DocGo | I 55% Oak Street 7% Oak Street (c) Pro forma for Livongo Health acquisition. Source: Company information, FactSet. Market data as of 18-May-21. 98% Oak Street Healthcare Peers 30% One Medical 39% One Medical 29% One Medical 37% Accolade 45% (a)(b) 39% (b) Accolade (a)(b) Accolade 21% Signify 49% Signify 21% (a) Pro forma for the acquisition of 2ND.MD; 2019 figures represents standalone ACCD; excludes earnout consideration associated with the 2ND.MD acquisition. (b) Excludes the pending acquisition of Plushcare. Signify Virtual Care Peers 48% Teladoc 68% (c) Teladoc 48% (c) Teladoc 45% Hims&Hers 71% Hims&Hers 62% Hims&Hers DOCGO 31% Amwell 37% Amwell 26% Amwell Peer Group Average 37% Peer Group Median 45% Peer Group Medi an 39% Peer Group Median 24#262021E Multiples 2022E Multiples Comparable Company Benchmarking (cont'd) EV/2021E Revenue EV/2021E Gross Profit EV/2022E Revenue EV/2022E Gross Profit DocGo 5.6x © 2021 All Rights Reserved - DocGo DocGo 14.0x 3.4x DocGo DocGo I Oak Street 1 7.7x DocGo Note: Excludes multiples >100.0x. (a) Excludes the pending acquisition of Plushcare. 11.9x Oak Street NM 7.6x Oak Street 68.7x Source: Company information, FactSet. Market data as of 18-May-21. Oak Street Healthcare Peers 9.8x One Medical 25.2x One Medical 7.9x One Medical 20.3x One Medical 10.9x Accolade 24.1x Accolade 8.4x (a) 18.4x (a) Accolade (a) Accolade 8.2x Signify 16.6x Signify 6.9x Signify 13.7x Signify 12.2x Teladoc 18.0x Virtual Care Peers Teladoc 9.5x Teladoc 13.8x Teladoc 8.0x Hims&Hers 11.4x Hims&Hers 6.8x Hims&Hers 9.1x Hims&Hers DOCGO 8.9x Amwell 24.1x Amwell 7.1x Amwell 17.1x Amwell Peer Group Median 9.8x Peer Group Median 21.0x Peer Group Medi an 7.6x Peer Group Medi an 17.1x Peer Group Medi an 25#27D Appendices#28Non-GAAP Adjusted EBITDA Reconciliation DOCGO Note: PCAOB audits for 2020 are in process. © 2021 All Rights Reserved - DocGo ($ in thousands) Net Loss Attributable to DocGo (+) Loss of JV Net Loss (GAAP) (+) Net Interest Expense / (Income) (+) Income Tax (+) Depreciation & Amortization EBITDA (+) Non-Cash Stock Compensation (+) Non-Recurring Expense Adjusted EBITDA CY2020E ($15,049) (213) ($15,262) 608 167 5,689 ($8,798) 687 1,000 ($7,111) 27

Download to PowerPoint

Download presentation as an editable powerpoint.

Related

Fiscal 3Q Investor Presentation image

Fiscal 3Q Investor Presentation

Healthcare

FY23 Full-Year Results Presentation image

FY23 Full-Year Results Presentation

Healthcare

Healthcare Network P&L Statement and Expansion Projects image

Healthcare Network P&L Statement and Expansion Projects

Healthcare

Accreditation and Quality Assurance Overview image

Accreditation and Quality Assurance Overview

Healthcare

Investment Highlights image

Investment Highlights

Healthcare

Investor Presentation image

Investor Presentation

Healthcare

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update image

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

Healthcare

BioAtla Investor Presentation Deck image

BioAtla Investor Presentation Deck

Healthcare